<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=EBQ_talk%3AProCESS_Trial</id>
	<title>EBQ talk:ProCESS Trial - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=EBQ_talk%3AProCESS_Trial"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ_talk:ProCESS_Trial&amp;action=history"/>
	<updated>2026-05-01T20:13:11Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=EBQ_talk:ProCESS_Trial&amp;diff=18506&amp;oldid=prev</id>
		<title>Ostermayer: /* Protocol vs Non Protocol */ new section</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ_talk:ProCESS_Trial&amp;diff=18506&amp;oldid=prev"/>
		<updated>2014-03-19T20:12:32Z</updated>

		<summary type="html">&lt;p&gt;&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Protocol vs Non Protocol: &lt;/span&gt; new section&lt;/span&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 20:12, 19 March 2014&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Hey, I haven't read the paper yet.  When you say, &amp;quot;No significant 60 or 90 day mortality benefit was found to the '''protocol therapy''',&amp;quot; does &amp;quot;protocol therapy&amp;quot; refer to both the EGDT protocol group and the non-CVP, -inotrope, -transfusion protocol group or just the EGDT protocol group? -Ross&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Hey, I haven't read the paper yet.  When you say, &amp;quot;No significant 60 or 90 day mortality benefit was found to the '''protocol therapy''',&amp;quot; does &amp;quot;protocol therapy&amp;quot; refer to both the EGDT protocol group and the non-CVP, -inotrope, -transfusion protocol group or just the EGDT protocol group? -Ross&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;== Protocol vs Non Protocol ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Actually no statistical  differences were found among any of the groups. Protocol, Protocol-EGDT, and &quot;Usual Care&quot;.  I think we will spell it out to make it more clear in the review&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Ostermayer</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=EBQ_talk:ProCESS_Trial&amp;diff=18505&amp;oldid=prev</id>
		<title>Rossdonaldson1 at 17:32, 19 March 2014</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ_talk:ProCESS_Trial&amp;diff=18505&amp;oldid=prev"/>
		<updated>2014-03-19T17:32:30Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 17:32, 19 March 2014&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Hey, I haven't read the paper yet.  When you say, &amp;quot;No significant 60 or 90 day mortality benefit was found to the '''protocol therapy''',&amp;quot; does &amp;quot;protocol therapy&amp;quot; refer to both the EGDT protocol group and the non-CVP, -inotrope, -transfusion protocol group or just the EGDT protocol group?&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Hey, I haven't read the paper yet.  When you say, &amp;quot;No significant 60 or 90 day mortality benefit was found to the '''protocol therapy''',&amp;quot; does &amp;quot;protocol therapy&amp;quot; refer to both the EGDT protocol group and the non-CVP, -inotrope, -transfusion protocol group or just the EGDT protocol group? &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;-Ross&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Rossdonaldson1</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=EBQ_talk:ProCESS_Trial&amp;diff=18504&amp;oldid=prev</id>
		<title>Rossdonaldson1: Created page with &quot;Hey, I haven't read the paper yet.  When you say, &quot;No significant 60 or 90 day mortality benefit was found to the '''protocol therapy''',&quot; does &quot;protocol therapy&quot; refer to bot...&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ_talk:ProCESS_Trial&amp;diff=18504&amp;oldid=prev"/>
		<updated>2014-03-19T17:32:15Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;Hey, I haven&amp;#039;t read the paper yet.  When you say, &amp;quot;No significant 60 or 90 day mortality benefit was found to the &amp;#039;&amp;#039;&amp;#039;protocol therapy&amp;#039;&amp;#039;&amp;#039;,&amp;quot; does &amp;quot;protocol therapy&amp;quot; refer to bot...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Hey, I haven't read the paper yet.  When you say, &amp;quot;No significant 60 or 90 day mortality benefit was found to the '''protocol therapy''',&amp;quot; does &amp;quot;protocol therapy&amp;quot; refer to both the EGDT protocol group and the non-CVP, -inotrope, -transfusion protocol group or just the EGDT protocol group?&lt;/div&gt;</summary>
		<author><name>Rossdonaldson1</name></author>
	</entry>
</feed>